NEW YORK (GenomeWeb News) – Metabolon said today that it has signed an intellectual property and development agreement with the University of Michigan related to its Prostarix line of prostate cancer diagnostics.
 
Under the terms of the agreement, Metabolon has taken an exclusive license for prostate cancer aggressiveness biomarkers that were discovered in a previous collaboration between the company and the university.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.